SNSS:NASDAQ

Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
SNSS:NASDAQ

Expert Comments:

Maxim Jacobs, Edison Investment Research (4/24/17)
"Sunesis Pharmaceuticals Inc. lead program is Qinprezo, a quinolone derivative for relapsed/refractory acute myeloid leukemia without the dose limiting cardiotoxicity of anthracyclines. . .significant potential remains in Europe where Qinprezo has data comparable to those used in other approvals. . .Sunesis is also advancing its clinical asset, SNS-062, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile with twice a day dosing . .Phase Ib/II is expected to begin in 1H17."

Maxim Jacobs, Edison Investment Research (3/23/17)
"Sunesis Pharmaceuticals Inc.'s lead program is Qinprezo, a quinolone derivative for relapsed/refractory acute myeloid leukemia (AML) without the dose limiting cardiotoxicity of anthracyclines. The FDA discouraged submitting an NDA after it missed its primary endpoint, but significant potential remains in Europe. . .a decision by CHMP is expected by mid-2017. . .SNS-062, a novel non-covalent, oral BTK inhibitor may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile. . .a Phase Ib/II is expected to begin in H117."

Maxim Jacobs, Edison Investment Research (3/15/17)
"Sunesis Pharmaceuticals Inc.'s application for EU approval for vosaroxin in AML continues to progress. . .we continue to expect a launch in H2/17. . .the company plans to initiate a Phase Ib/II study of SNS-062, their BTK inhibitor, in patients with various advanced B-cell malignancies in H1/17. . .we have increased our valuation slightly to $219m or $10.47 per basic share."

Maxim Jacobs, Edison Investment Research (2/16/17)
"Sunesis Pharmaceuticals Inc. is advancing its clinical asset, SNS-062, a novel non-covalent, oral Bruton's tyrosine kinase inhibitor that may work in Imbruvica-relapsed and -refractory patients. Data from a Phase 1a study in healthy volunteers was recently presented and indicated an attractive pharmacokinetic/pharmacodynamic profile with twice a day dosing; a Phase 1b/2 is expected to begin in H1/17."

Jim Birchenough, Wells Fargo Securities (1/31/17)
"Wells Fargo Securities biotechnology team hosted Sunesis Pharmaceuticals Inc. on a non-deal roadshow with investors. . .with regards to QINPREZO, SNSS appears increasingly confident in prospects for approval following review of 180-day question from the European Medicines Agency and expects to submit a final response in March with Scientific review in April and a decision by late April/May. . .we are reiterating our OUTPERFORM rating. . .with potential approval of QINPREZO, high value partnership to eliminate the balance sheet risk, and potential blockbuster opportunity with SNS062, we believe that SNSS is undervalued relative to this opportunity and would be buyers here."

Zacks Equity Research (1/23/17)
"Sunesis Pharmaceuticals Inc. loss estimates narrowed 5.06% and 8.80% for 2017 and 2018, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%."

More Expert Comments

Experts Following This Company

Jim Birchenough – BMO Capital Markets
Maxim Jacobs – Edison Investment Research
Hartaj Singh, Biotechnology Analyst – BTIG Research

The information provided above is from analysts, newsletters, the company and other contributors.

Sunesis Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Totality of VALOR data shows compelling risk-benefit trade-off in disease with significant unmet need
 
Relapsed/refractory AML is a significant commercial opportunity with no approved agents
Sunesis Pharmaceuticals Inc. Content